The Global Glucagon Like Peptide-1 (GLP-1) Agonists Market was valued at USD 8.82 Billion in 2023 and is projected to reach USD 27.12 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 13.3% during the forecast period (2023-2032). This robust expansion reflects the escalating global diabetes epidemic (affecting 537 million people as of 2021 per IDF data) and the superior clinical benefits of GLP-1 therapies for glycemic control and weight management.
As healthcare systems prioritize metabolic disease management, pharmaceutical innovators are advancing novel GLP-1 formulations with improved efficacy and convenience. Here we examine the Top 10 Companies in the GLP-1 Agonists Market—sector leaders driving therapeutic innovation through cutting-edge research and strategic commercialization.
🔟 1. Novo Nordisk A/S
Headquarters: Bagsværd, Denmark
Key Products: Victoza® (liraglutide), Ozempic® (semaglutide), Rybelsus® (oral semaglutide)
Novo Nordisk commands a 53.1% global GLP-1 market share, demonstrating dominance through continuous peptide therapeutics innovation. Their blockbuster Ozempic established new benchmarks for weekly diabetes therapy, showing superior cardiovascular outcomes versus competitors.
Clinical Advantages:
- Phase 3 data shows A1C reduction up to 1.8% with Ozempic
- Rybelus® pioneers first oral GLP-1 formulation (2020 FDA approval)
- Pioneered cardiovascular risk reduction labeling
Download FREE Sample Report: Glucagon Like Peptide-1 (GLP-1) Agonists Market – View in Detailed Research Report
9️⃣ 2. Eli Lilly and Company
Headquarters: Indianapolis, Indiana, USA
Key Products: Trulicity® (dulaglutide), Mounjaro® (tirzepatide)
Eli Lilly’s dual GIP/GLP-1 receptor agonist Mounjaro® achieved industry-leading Phase 3 results with 2.4% A1C reduction and 11.7% weight loss, positioning it as Novo Nordisk’s primary competitor.
Market Expansion:
- FDA approved obesity indication (2023)
- $1.6 billion investment in new manufacturing facilities
- Strategic partnerships with 12 major pharmacy chains
8️⃣ 3. Sanofi
Headquarters: Paris, France
Key Product: Adlyxin® (lixisenatide)
Sanofi maintains a strategic position in European and Asian markets with Adlyxin®, focusing on patients requiring postprandial glucose control despite its smaller market share (6.3%).
Innovation Focus:
- Licensing agreement with Zealand Pharma for next-gen GLP-1 agents
- Digital therapeutics integration for medication adherence
- Emerging market access programs
7️⃣ 4. AstraZeneca PLC
Headquarters: Cambridge, UK
Key Product: Byetta® (exenatide), Bydureon® (exenatide extended-release)
AstraZeneca’s exenatide franchise remains clinically relevant through lifecycle management, particularly the once-weekly Bydureon BCise® autoinjector system launched in 2017.
Strategic Developments:
- SGLT2/GLP-1 fixed-dose combinations in development
- Expanded manufacturing capacity in emerging markets
- 200+ clinical studies completed on exenatide formulations
Download FREE Sample Report: Glucagon Like Peptide-1 (GLP-1) Agonists Market – View in Detailed Research Report
6️⃣ 5. Pfizer Inc.
Headquarters: New York, USA
Pipeline Status: Phase 2 GLP-1 candidates
Pfizer is leveraging its biologics expertise to develop next-generation GLP-1 therapies with improved delivery systems and combination mechanisms.
R&D Investments:
- $850 million metabolic research budget
- Novel oral and implantable delivery technologies
- Three clinical-stage GLP-1 candidates
5️⃣ 6. Bristol-Myers Squibb
Headquarters: New York, USA
Strategic Move: Partnership with Zealand Pharma
BMS entered the GLP-1 space through collaboration with Zealand Pharma to develop novel peptide therapeutics targeting metabolic disorders.
Collaboration Highlights:
- $250 million upfront payment to Zealand
- Focus on differentiated MOA candidates
- Phase 2 candidate expected 2024
4️⃣ 7. Hanmi Pharmaceutical
Headquarters: Seoul, South Korea
Key Innovation: Efinopegdutide (Phase 3)
Hanmi’s GLP-1/glucagon dual agonist represents a novel therapeutic approach with potential advantages in hepatic glucose control and weight management.
Development Milestones:
- Fast Track designation (FDA)
- Asian market focus
- Strategic licensing to US/EU pharma
3️⃣ 8. Zealand Pharma
Headquarters: Copenhagen, Denmark
Core Competency: Peptide technology platform
Zealand’s proprietary peptide discovery engine powers multiple partnered GLP-1 programs, generating substantial royalty revenues.
Technology Edge:
- 15+ peptide drug candidates in development
- Patented stabilization technologies
- Three partnered GLP-1 programs
Download FREE Sample Report: Glucagon Like Peptide-1 (GLP-1) Agonists Market – View in Detailed Research Report
2️⃣ 9. Amylin Pharmaceuticals
Historical Contribution: Byetta® (first GLP-1 agonist)
Though acquired by AstraZeneca in 2012, Amylin’s legacy includes pioneering the GLP-1 class with the FDA approval of Byetta® in 2005.
Industry Impact:
- Established proof-of-concept for GLP-1 efficacy
- Developed initial formulation technologies
- Launched first GLP-1 patient education programs
1️⃣ 10. GlaxoSmithKline (GSK)
Historical Product: Tanzeum® (albiglutide)
GSK’s discontinued Tanzeum® contributed valuable insights about dosing convenience and formulation stability that informed subsequent market developments.
Scientific Legacy:
- First albumin-fused GLP-1 analog
- Pioneered disposable autoinjector
- Key safety dataset for class
📈 Market Trends and Future Outlook
The GLP-1 market is evolving beyond diabetes into obesity, NASH, cardiovascular disease, and potential CNS applications, with annual growth projected at 13.3% through 2032.
Key Growth Drivers:
- Expanding obesity treatment approvals
- Novel dual/triple agonist mechanisms
- Improved delivery systems (oral, implantable)
- Cardiovascular outcome benefits
Therapeutic Area Market Share:
- Type 2 Diabetes: 62.4%
- Obesity: 31.8% (fastest growing)
- Other: 5.8%
Regional Market Dynamics:
- North America: 51.3% market share
- Europe: 27.9%
- Asia-Pacific: 16.2% (22% CAGR)
The profiled companies exemplify pharmaceutical innovation, transforming metabolic disease treatment paradigms through scientific excellence and strategic execution.
Get Full Report Here: Glucagon Like Peptide-1 (GLP-1) Agonists Market – View in Detailed Research Report